Lowest Price Guaranteed From USD 4,799
The biopharmaceutical excipients market is estimated to be worth $2.2 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 5.8% during the forecast period. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. However, biological therapeutics are inherently less stable than small molecules and, hence, more prone to degradation by several physical and chemical degradation mechanisms. Therefore, a variety of pharmaceutical excipients for biologics, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Furthermore, pharmaceutical excipients for biologics play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs). Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives. As a result, the demand for pharmaceutical excipients for biologics has grown considerably. However, for some of the biopharmaceutical excipients, such as lipids, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges. Some of the major issues related to the production of GMP grade biopharmaceutical excipients include the need for specialized expertise, lack of facilities with the necessary infrastructure and capacity to produce the required quality of substances, as well as concerns related to storage, safety and efficacy.
Considering the technical and routine operations-related challenges, an increasing number of biologics developers are increasingly relying on biopharmaceutical excipient manufacturers. The benefits of engaging such third-party service providers are numerous; for instance, contracting a supplier for medical grade biopharmaceutical excipients enables sponsors to leverage specialty biopharmaceutical excipients (available with the manufacturers), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers that claim to have the required capabilities to manufacture a variety of biopharmaceutical excipients, including lipids, lactose, trehalose, mannitol, succinate, Tween 20 and benzyl alcohol. These companies are increasingly focusing on the development of co-processed multifunctional biopharmaceutical excipients to improve the stability and effectiveness of novel biotherapeutics. It is worth highlighting that biopharmaceutical excipient manufacturers are actively trying to consolidate their presence in biopharmaceutical excipients market by entering into strategic alliances, enhance their respective manufacturing capabilities in order to meet the growing demand for pharmaceutical excipients for biologics. In fact, recently, a number of deals were inked between vaccine developers and biopharmaceutical excipient manufacturers in order to cater to the urgent need for lipids for the formers’ respective COVID-19 vaccines. With outsourcing being increasingly accepted as a viable and beneficial business model within biopharmaceutical excipients market, we anticipate the biopharmaceutical excipients market to witness a steady market growth during the forecast period.
Examples of key excipient manufacturers engaged in biopharmaceutical excipients market (which have also been profiled in this market report; the complete list of companies is available in the full report) include ABITEC, Avantor, BASF Pharma, Corden Pharma, DFE Pharma, Evonik, Kirsch Pharma, Merck KGaA, Pfanstiehl, Roquette, Spectrum Chemical Manufacturing and SPI Pharma. This market report includes an easily searchable excel database of all the excipient manufacturers providing biopharmaceutical
Several recent developments have taken place in the field of biopharmaceutical excipients market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Biopharmaceutical Excipients Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035’ market report features an extensive study of companies engaged in manufacturing of biopharmaceutical excipients. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in biopharmaceutical excipients market.
Amongst other elements, the market report features:
One of the key objectives of this market research report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity of the biopharmaceutical excipients market during the forecast period. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of biologics (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.